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Abstract
Purpose: To evaluate the clinical outcome of early glottic cancer (GC) treated by primary radiotherapy (RT) with 6
MV photons.
Methods and materials: We retrospectively reviewed the medical records of 695 consecutive patients with T1N0
and T2N0 GC treated between 1983 and 2005 by RT in our institution. Clinical outcome in terms of local control
(LC), overall survival (OS) and cause- specific survival (CSS) rate were evaluated.
Results: The median follow-up time was 10.5 years. The 10-year actuarial LC rates were as follows: T1A, 91%; T1B,
87%; T2, 77%. The 10-year OS were as follows: T1, 74.2%; T2, 70.7%. The 10-year CSS were as follows: T1, 97.7%; T2,
97.1%.
Poorly differentiated histology and tumor biologically effective dose < 65 Gy15 were adverse factors in both LC of T1
and T2 disease. Involvement of anterior commissure was an adverse factor in both LC and CSS of T1 disease.
Subglottic extension was associated with poor LC in T2 disease whereas hemoglobin <13.0 was associated with
poor LC and CSS of T2 disease.
Conclusion: Primary RT remains an option among the various standard treatments for early GC. Clinical treatment
outcome by 6MV photons is similar and comparable to historic data of Cobalt-60 and 2 MV photons.
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Introduction
Laryngeal cancer is the third most common head and
neck (H&N) cancer in Hong Kong. According to Hong
Kong Cancer Registry, the age-standardized incidence
rate was 2.3 per 100,000 in 2007[1].
In western countries, definitive radiotherapy (RT) and
conservative surgery (endoscopic laser surgery/open organ
preserving surgery) are accepted standard treatment mo-
dalities for early stage laryngeal cancers. The axiom of
treatment aims for cure with laryngeal preservation and
maintain optimal quality of life like voice quality and swal-
lowing. The choice of treatment depends on availability of
facilities and medical expertise, as well as patient’s prefer-
ence and the cost of treatment [2,3].
A survey conducted to eleven Asian regions/countries
about management strategy of early laryngeal cancer
revealed that around half of the countries/regions, espe-
cially those follow the British stream, like Hong Kong
and Singapore, primary radiotherapy remained a main-
stay treatment modality [4]. In Hong Kong, around 95%
of early glottic cancer (GC) patients were treated by pri-
mary radiotherapy (RT) alone.
For definitive RT, there is extensive published data
regarding management of early GC with Cobalt-60 or 2-4
MV photons. Factors studied for prognostic importance
for local failure included pretreatment hemoglobulin [5],
sex [5,6], T category [5,7], histology differentiation [7], an-
terior commissure involvement [6], subglottic extension
[5], tumor bulk [5,6,8], fraction dose size [7] and overall
treatment time [7].
The reported treatment outcome of early GC by primary
RT with 6MV photons is limited. We present our institu-
tion’s experience in this report.
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Patient characteristics
In Hong Kong, most citizens are not covered by medical
insurance and their medical care is provided mainly by
the public care system funded by the Government. The
Queen Elizabeth Hospital is one of the major public ter-
tiary referral centers.
In May 2010, we conducted a retrospective review of la-
ryngeal cancer patients referred to our center over a
23 year period for radical treatment between January 1983
to December 2005. A total of 1256 consecutive patients
were identified. According to the Hong Kong Cancer
Registry, about a quarter of laryngeal cancer cases diag-
nosed in Hong Kong over that period had been treated in
our institution.
Out of the 1256 patients, there were 695 previously un-
treated patients with T1N0 and T2N0 GC. Six hundred
and sixty- two were male and 33 female patients, with a
male: female ratio of 20:1. Six hundred and eighty two
(98%) were Chinese and 13 (2%) came from other ethic
backgrounds. Age ranged from 35 to 94 (median: 65). As
the treatment of choice at our institution for stage I and II
GC has always been primary RT alone, this represented a
relatively unselected cohort of patients.
Staging
All patients had full physical examination, routine blood
counts, renal and liver function tests, chest x ray, endo-
scopic examination and biopsy for histology diagnosis.
Computed tomography (CT) scan of larynx and neck
was performed in 661 (95%) patients. All patients were
restaged according to TNM 2002 classification [9].
Table 1 summarizes the patient and tumor parameters.
Radiotherapy treatment
All patients were treated exclusively with 6-MV photons.
They were treated in a supine position, immobilized
with a customized neck cast. All patients received a con-
tinuous course of RT with once-daily fractionation, 5
fractions per week. All fields are equally weighted and
treated in each fraction. Appropriate wedge filters were
used to improve the dose homogeneity. 0.5 cm wax
bolus was used for disease involving the anterior com-
missure (AC). Table 2 summarizes the treatment
parameters.
Field size and set up
T1N0
All patients with T1 disease were treated with parallel-
opposed fields, to cover the glottic larynx with 1-2 cm
margins. The field size was obtained by multiplying the
field length by the field height. They ranged from 22-
38.5 cm2 (median: 27.5 cm2). Typically, the superior
border was placed at around the superior border of thethyroid cartilage, the inferior border was placed at
around the bottom of the cricoid cartilage, the anterior
border extending beyond the skin surface and the pos-
terior border stopping at the anterior border of the ver-
tebral body of cervical spine. Elective nodal irradiation
was not given.
T2N0
Two hundred and thirty eight (90.8%) of T2 patients
were treated with parallel opposed fields. Although the
initial field sizes ranged from 35 to 72 cm2 (median: 42),
82% of patients were treated with 42 cm2 (6 cm x 7 cm)
or smaller portals.
Twenty one (8%) patients were treated with a single
anterior appositional field, in which electron beam were
used after the initial 30 Gy given by 6 MV photon beam.
Three (1.1%) patients were treated with a three- field
technique by adding an anterior field to two opposing
fields.
Dose and fractionation
Dose was prescribed at the midline along the central axis
or recalculated at the ICRU reference point. Between the
period of 1983- 1988 and 1996- 2005, patients were trea-
ted with a fraction size of 2.0 Gy whereas during 1989-
1995, a fraction size of 2.5 Gy was utilized because of
constraints in linear accelerator machine in the hospital.
To allow comparison of dose prescribed in different
periods, we opted to compute the tumor biologically ef-
fective dose (BED) by using the standard linear quadratic
formula (LQ) with time factors corrected [10]:
Tumor BED ¼ nd 1þ d= α=β½ ð Þ
 loge 2 T  Tkð Þ=αTp
where n fractions of d Gy are given in an overall time of
T days and kick off time (Tk) for tumor repopulation.
We assume α/β= 15 for laryngeal cancer[11], Tk = 28 for
tumor [12], Tp = average cell number doubling time dur-
ing continuing radiation, 3 days for tumor [13]. Alpha
(α) = 0.35 Gy-1 [13][coefficient of non-repairable injury,
log cell kill (exponentially-based logs) per gray of dose].
T1N0
During 1983-1988 and 1996-2005, the dose-fractionation
schedule was 66 Gy in 33 fractions whereas during
1989- 1995, the schedule was 57.5 Gy in 23 fractions.
T2N0
During 1983 – 1988, the dose- fractionation schedule
was 66 Gy in 33 fractions whereas during 1989-1995,
the schedule was 57.5 Gy in 23 fractions. Since 1996, we
have prescribed up to 70 Gy in 35 fractions for all T2
disease.
Table 2 Treatment parameters
Parameters Stage T1N0 Stage T2N0
(433) Patients (%) (262) Patients (%)
Field size (cm2)
< 30.5 215 (49.6) 0
30.5- 35.5 165 (38.1) 106 (40.4)
≥ 35.5 53 (12.2) 156 (59.5)
A. Dose fraction size
2.5 Gy 177 (40.8) 86 (32.8)
Total dose (Gy)
55 30 (6.9) 7 (2.7)
57.5 134 (30.9) 63 (24.0)
60 13 (3.0) 16 (6.1)
Tx duration (days)
30 25 (5.7) 22 (8.4)
31-34 141 (32.5) 45 (17.1)
≥ 35 11 (2.5) 19 (7.2)
BEDcGy15 (cGy)
Median 6520 6580
range 6058- 6820 6160- 6820
B. Dose fraction size
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All patients underwent evaluation of response to treat-
ment by endoscopy examination at 6 to 8 weeks after
completion of RT treatment. Patients were regularly
seen once every three months during the initial 2 years
and then six-monthly up to 5 years and then yearly
thereafter.
Complications
Acute and chronic complications were scored according
to the Common Terminology Criteria for Adverse Events
version 3.0 [14].
Statistical analysis
Local and neck failure was defined as clinically/radio-
logical detectable disease in larynx and cervical lymph
node (LN) respectively. Distant metastasis (DM) was
defined as clinically or radiologically detectable disease
outside the larynx and cervical LN. Clinicopathologic
parameters that were analyzed included age (<61 vs. 61-70
vs. >71), gender (male vs. female), pre-treatment
hemoglobin (Hb) level (<13.0 vs. ≥13.0 g/dl), T sub-stage
(T1a vs. T1b) [for T1 disease], impaired cord mobility (yesTable 1 Patient and tumor parameters
Parameter T1N0 T2N0
Patient no. (%) Patient no. (%)
All stages 433 262
T1a 324 (74.8%) -
T1b 109 (25.1%) -
Gender
Male 413 (95.3%) 249 (93.8%)
Female 20 (4.6%) 13 (4.9%)
Grade
Well differentiated 154 (35.5%) 64 (24.4%)
Mod differentiated 273 (63.0%) 179 (68.3%)
Poorly differentiated 6 (1.3%) 19 (7.2%)
Anterior commissure involved
Yes 197 (45.4%) 186 (71%)
No 236 (54.1%) 76 (29%)
Impaired mobility
Yes Not apply 51 (19.4%)
No 211 (80.5%)
Sub-glottic extension
Yes Not apply 80 (31%)
No 182 (69%)
Hb level
< 13 g/dL 45 (10.4%) 28 (10.6%)
≥ 13 g/dL 388 (89.6%) 234 (91.4%)
Abbreviations: no. = number; Hb =Hemoglobin.
2.0 Gy 256 (59.1) 176 (67.1)
Total dose (Gy)
64 52 (12.0) 24 (9.1)
66 202 (46.6) 109 (41.6)
68 2 (0.46) 2 (0.7)
70 0 41 (15.6)
Tx duration (days)
≤45 48 (11.0) 18 (6.8)
46- 50 203 (46.8) 110 (42.0)
≥ 51 5 (1.15) 48 (18.3)
BEDcGy15 (cGy)
Median 6340 6520
range 6040- 6700 6040- 6910
Abbreviations: Tx = treatment; BED =biologically effective dose.vs. no) [for T2 disease], tumor grading (well vs. moderate
vs. poorly differentiated squamous cell carcinoma) and in-
volvement of AC (yes vs. no). Treatment parameters
included dose fraction size (2.0 Gy vs. 2.5 Gy), BEDGy15
given (<65.0 Gy15 vs. ≥ 65.0 Gy15), treatment field size in
cm2 (< 30.5 vs. 30.5 – 35.5 vs. > 35.5), and treatment
period (1983- 1990 vs. 1991- 2000 vs. 2001- 2005).
All time-related events were measured from date of the
first RT treatment. The actuarial local control (LC) rate, ul-
timate LC rate, cause- specific survival (CSS) and overall
survival (OS) were calculated by the Kaplan-Meier method.
Difference of the endpoints of patient cohorts stratified by
various prognostic factors were evaluated by the Log- rank
Figure 1 Clinical course. Abbreviations: pts = patients; RT = radiotherapy; TL = total Laryngectomy; RND= radical neck dissection;
PLO=pharyngolaryngectomy; 1st = First; 2nd = Second.
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univariate and multivariate analysis to determine the
hazard ratios and significance of potential risk factors for
LC and CSS. All statistical tests were two-sided andFigure 2 Actuarial local control.performed at the 0.05 level of significance (p value). Only
factors with a level of significance less than 0.05 in univari-
ate analysis would be further analyzed in the multivariate
analysis. We used SPSS, version 15.0, (SPSS Inc.,Chicago,
IL) for all statistical analyses.
Results
Local and neck control
The clinical course of this patient cohort is shown in
Figure 1. The median follow- up period was 10.5 years
(range: 3.3-26 years). LC after primary RT is depicted in
Figure 2. The 5-year and 10-year actuarial LC rates were
as follows: T1A, 92% and 91%; T1B, 89% and 87%; T2,
79% and 77% respectively.
Complete response was achieved in 679 (97.6%)
patients, while 16 (2.3%) patients (3 T1 and 13 T2) had
residual disease at vocal cord(s). Seventy three (10.5%)
among the 679 patients who achieved complete response
had first relapse with a median time of 15 months. The
first sites of relapse included: vocal cord(s) only in 68
Table 3 Univariate and multivariate analysis of factors affecting local control
T1N0 T2N0
Parameters Event/pts Uni-variate Multivariate analysis Event/pts Uni-variate Multivariate analysis
P value Hazard ratio (95% CI) P value P value Hazard ratio (95% CI) P value
Age




Male 41/413 0.445 - NS 55/249 0.831 - NS
Female 1/20 3/13
Substage
T1A 28/324 0.24 - NS NA - - -
T1B 14/109
Grade
Well diff 9/154 0.0001* 1 0.035* 10/64 0.025* 1
Moderate diff 29/273 1.91 (1.2- 3.85) 40/179 2.4 (1.7- 3.2) 0.022*
Poorly diff 4/6 7.5(3.42- 5.24) 8/19 4.3(2.6- 8.9)
Impaired Cord mobility
yes NA - - - 11/51 0.53 - NS
No 47/211
Subglottic Extension
Yes NA - - - 23/80 0.038* 2.15 (1.78-5.51) 0.027*
No 35/182 1
Hb (g/dL)
< 13.0 6/45 0.367 - NS 15/28 0.001* 3.78 (1.34-8.40) 0.031*
≥ 13.0 36/388 43/234 1
AC
No 14/236 0.004* 1 0.011* 12/76 0.129 - NS
Yes 28/197 2.34 (1.21-4.52) 46/186
Field size (cm2)
<30.5 35/215 0.534 - NS 0 0.138 - NS
30.5- 35.5 7/165 26/106
> 35.5 0/53 32/156
Dose size
2.0 Gy 32/256 0.021* 2.17 (1.28- 4.18) 0.035* 45/176 0.042* - NS
2.5 Gy 10/177 1 13/86
BEDGy15
< 65.0 36/315 0.025* 3.38 (1.29- 7.83) 0.017* 12/76 0.022* 1.8 (1.2- 5.74) 0.038*
≥ 65.0 6/118 1 46/186 1
Tx period
1983- 1990 10/115 0.643 - NS 17/75 0.336 - NS
1991- 2000 25/224 29/142
2001- 2005 7/94 12/45
Abbreviations: pts = patients; Hb = hemoglobin; Tx = treatment; diff = differentiated; AC = anterior commissure; BED=biologically effective dose; * = statistically
significant; NS = not significant.
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1st Failures pts Types of 1st salvage surgery 2nd Relapse Pts 2nd salvage surgery Ultimate
failure
Pts (%)
(No. salvaged/No. attempted) (No salvage/attempted)
local LN Local + LN Total (%) TL RND TL+RND Not fit/refused surgery
T1 433 39 0 0 39 (9) 36 0 0 3 7 0/7 10 (2.3)
T2 262 45 2 3 50 (19%) 43 2 2 3 3 2/3 (PLO) 7 (2.6)
Abbreviations: No= number; pts = patients; 1st = first; 2nd = second; LN = lymph node; TL = total Laryngectomy RND= radical neck dissection;
PLO=pharynolaryngectomy.
Tong et al. Head & Neck Oncology 2012, 4:23 Page 6 of 10
http://www.headandneckoncology.org/content/4/1/23(10%) patients (38 T1 and 30 T2), regional LN only in 2
(0.2%) patients (2 T2), vocal cord(s) plus regional LN in
3 (0.4%) patients (3 T2).
Table 3 showed parameters that have prognostic signifi-
cance on LC. For T1 disease, on multivariate analysis, LC
was adversely affected by the poorly differentiated hist-
ology (Hazard Ratio [HR]: 7.5, p=0.035), involvement of
AC (HR: 2.34, p=0.011), fraction dose size of 2.0 Gy (HR:
2.17, p=0.035) and tumor BED Gy15 < 65.0 Gy15 (HR:
3.38, p=0.017).
For T2 disease, on multivariate analysis, LC was ad-
versely affected by poorly differentiated grading (HR: 4.3,
p=0.022), Hb<13.0 (HR: 3.78, p=0.031), subglottic exten-
sion (HR: 2.15, p=0.027) and tumor BED Gy15 < 65.0 Gy15
(HR: 1.8, p=0.038).
Salvage surgery and ultimate control
Table 4 showed the details of the radical salvage surgery
performed for the 83 patients with residual disease or
first relapses. Ultimate disease control was achieved in
678 (97.5%) patients. The 10-year ultimate LC rates for
T1 and T2 disease was 97.6% and 97.4% respectively.
Larynx preservation was achieved in 606 (87%) patients.
Survival
At the last follow up, 272 patients had died: 15 from glot-
tic carcinomas, 118 from second malignancy and 138 fromFigure 3 Overall survival.intercurrent disease. Figures 3 and 4 showed the OS and
CSS for the entire cohort respectively. For T1 disease,
multi-variate analysis showed involvement of AC is the
only independent adverse factor for CSS (HR: 3.7,
p=0.045). For T2 disease, haemoglobin <13.0 is the only
independent adverse factor for CSS (HR: 2.8, p=0.028)
[Table 5].Complications
Regarding acute radiation toxicity, there was no incidence
of grade 3 or higher acute complications in T1 disease. For
T2 disease, 9 (1.2%) patients experienced grade 3 acute ra-
diation toxicity, with an incidence of 9/86 [10.4%] in
patients treated with 2.5 Gy compared with none in those
treated with 2.0 Gy (chi-square test value: p=0.001). Eight
of them had severe odynophagia and grade III confluent
mucositis, requiring nasogastric tube feeding or admission
for intravenous fluid supplement. All of them needed treat-
ment interruption of more than 4 treatment days. One pa-
tient developed grade IV laryngeal edema and necessitated
temporary tracheostomy during the last week of RT and ul-
timately treatment was prematurely terminated after 55 Gy
delivered over 22 fractions. There is no treatment death
related to acute radiation toxicity. For chronic complica-
tion, no clinical or radiological chondroradionecrosis that
warrants laryngectomy has been observed.Figure 4 Cause specific survival.




Uni-variate Multivariate analysis Event/pts Uni-variate Multivariate analysis
P value Hazard ratio (95% CI) P value P value Hazard ratio (95%CI) P value
Age




Male 10/413 0.459 - NS 5/249 0.61 - NS
Female 0/20 0/13
Substage
T1A 7/324 0.53 - NS NA - - -
T1B 3/109
Grade
Well diff 3/154 0.825 - NS 1/63 0.721 NS
Mod diff 7/273 3/179
Poorly diff 0/6 1/20
Impaired Cord mobility
yes NA - - - 1/51 0.84 NS
No 4/211
Subglottic Extension
Yes NA - - - 2/80 0.56 - NS
No 3/182
Hb (g/ dL)
< 13.0 1/45 0.76 - NS 1/28 0.022* 2.8 (1.5-7.8) 0.028*
≥ 13.0 9/388 4/234 1
AC
No 2/236 0.026* 1 0.045* 1/76 0.712 - NS
Yes 8/197 3.7 (1.20-18.5) 4/186
Field size (cm2)
<30.5 6/217 0.642 - NS 0 0.42 - NS
30.5- 35.5 4/165 2/106
> 35.5 0/53 3/156
Dose size
2.0 Gy 7/256 0.463 - NS 4/176 0.513 - NS
2.5 Gy 3/177 1/86
BED Gy15
< 65.0 8/315 0.661 - NS 4/175 0.534 - NS
≥ 65.0 2/118 1/87
Tx period
1983- 1990 1/115 0.287 - NS 0/75 0. 334 - NS
1991- 2000 6/224 4/142
2001- 2005 3/94 1/45
Abbreviations: pts = patients; Hb = hemoglobin; Tx = treatment; diff = differentiated AC = anterior commissure; BED =biologically effective dose; * = statistically
significant; NS = not significant.
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Table 6 Published local control and survival rate of early GC treated with 6 MV definite radiotherapy
Author (year) Patient number Local Control (%) OS (%) CSS (%)
[ref] 5 year*, 10 year # 5 year *, 10 year# 5 year*, 10 year#
Warde et al. [5] T1 + T2: 72 T1a: 91* T1 + T2: 75.8* NA
T1b: 82*
T2: 69*
Lee et al. [18] T1: 86 T1a: 82.2* T1: 85* NA
T2: 29 T1b: 76.2* T2: 74*
T2: 68.1*
Franchin et al. [23] T1: 323 T1: 90# T1: 66# NA
T2: 87 T2: 78# T2: 55#
Cellai & Frata et al. [6,7] T1: 35 T1: 84*, 83# T1: 77*, 57# T1: 95*, 93#
T2: 68 T2: 73*, 70# T2: 59*, 37# T2: 89*, 86#
Chera et al. [8] T1 + T2: 23 T1a: 94*, 93# T1 a: 82*, 62# T1a: 97*, 97#
T1b: 93*, 91# T1b: 83*, 57# T1b: 99*, 95#
T2a: 80*, 80# T2a: 76*, 51# T2a: 94*, 93#
T2b: 70*, 67# T2b: 78*, 49# T2b: 90*, 84#
Current series T1: 433 T1a: 92*, 91# T1: 89*, 74# T1: 98*, 97#
T1b: 89*, 87# T2: 89*, 70# T2: 98*, 97#
T2: 262 T2: 79*, 77#
Abbreviations: yr = year; NA= not available; OS = overall survival; CSS = cause specific survival.
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The debate on the optimal treatment options for early GC
has a long history, mainly because of absence of definitive
prospective randomized trials for comparing the various
treatment options [15]. A survey conducted in eleven
regions/countries in Asia revealed that in regions follow-
ing the ‘British school’ like Hong Kong and Singapore, RT
alone has remained the primary treatment modality for
early laryngeal cancers [4]. Vlantis et al. reviewed the treat-
ment results of laryngeal carcinoma in a single institution
in Hong Kong [16]. For early stage (T1 & T2) glottic
lesions, primary RT remained their mainstay of treatment.
As laser surgery become more popular since Steiner’s
landmark report [17], it is expected that it will be more
popular in local localities.
Focusing on primary irradiation, in many RT centers,
Cobalt 60 or 2-4 MV X-rays machines have been
decommissioned. It is anticipated that 6 MV photon
beams generated by LA will become the prevailing work-
horse for treatment in clinical practice [18]. Table 6
summarizes the published outcome results of early GC











2.0 35 70 47 66.79
2.5 23 57.5 31 65.28
Abbreviations: BED = biologically effective dose.There have been concerns about possible tumor
under-dosage when using 6MV or higher energy
photons for early GC. It has been reported that the lack
of electronic equilibrium at the air- tissue interface in
the laryngeal air cavity is more pronounced with both
higher- energy X rays and with small field size [19]. The
other issue is the lack of adequate buildup tissue in the
area where the neck is thin [20]. Izuno et al. observed a
significant inferior 5-year LC rate for T1N0 GC patients
when treated with 8/10-MV photons compared to Co60
(60% vs. 88%)[21].
Factors affecting local control
T1 disease
The factors of AC involvement, fraction dose size and
time dose factor affecting the LC rate of T1 disease has
been discussed in a separate article [22].
T2 disease
As noted, the LC rate of T2 disease treated with fractional
dose size of 2.5 Gy was superior to those treated with frac-
tion size of 2.0 Gy. However, this significance is lost inactionation scheme
D Acute Mucosal BED (Gy10) (aim
59-63 Gy10)[13]
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is the key factor to explain the significant difference which
is confirmed by the multi-variate analysis.
As shown in Table 7, the fractionation schedule of
2.5 Gy x 23 daily fractions can achieve a tumor
BEDGy15≥ 65 Gy15, however, it can also be associated with
a significant higher incidence of grade 3 acute radiation
toxicity as shown by the higher BEDGy10 for acute mucosa
and larger treatment field size in T2 disease.
Unlike our recommendation of using a fraction size of
2.5 Gy for T1 disease [22], our current practice for T2
disease is to prescribe 70 Gy in 35 fractions, 2 Gy per
fraction, 5 daily fractions per week. This can achieve a
tumor BED ≥ 65 Gy15 without an excess of grade 3 acute
mucosal toxicity.
Anaemia, poor differentiation of tumor grade and sub-
glottic extension are known reported adverse prognostic
factors in LC of GC [5,7,8] .
The impact of impaired cord mobility on LC of T2N0
GC is still controversial. Our data is consistent with
other published results that reported no prognostic sig-
nificance on LC [23,24] . However, other studies, includ-
ing a meta-analysis did suggest its adverse impact on LC
[7,25,26].
In view of the relatively inferior LC rate of T2 compared
with T1 disease, more intensive treatment strategies are
being explored. The role of bid hyperfractionation sched-
ule will become clear when the mature result of RTOG 95
-12 study become available. Another approach is the use
of concurrent chemotherapy. Nevertheless, there are some
data showing improvement of LC by platinum/5FU based
regimens [27,28] but others showed conflicting results
[29,30].
There are still controversies over the use of Intensity-
Modulated Radiotherapy (IMRT) for early stage GC. Fei-
genberg et al. warned about the treatment failure seen in
patient with early GC who received definite RT with
IMRT technique [31]. Their concerns were mainly errors
due to contouring errors and organ motion.
Some technical studies revealed IMRT technique per-
mit more irradiation dose sparing at carotid arteries and
might have favorable implication on long term risk of
cerebrovascular accident [32,33]. However, others still
continue to recommend conventional RT fields and
technique for treatment of patient with early stage GC
[34,35].
Conclusion
To the best of our knowledge, our report is the largest
study on RT outcomes in early GC primarily treated
with 6 MV photons. Both the LC and CSS rates of T1
and T2 disease in our series are comparable with other
reported data. This reassures the efficacy of 6 MV
photons used in primary RT for early GC. Nevertheless,the results of the current report is a retrospective, single
institution study and therefore can be subjected to
biases, especially other known significant prognostic fac-
tors including tumor volume and smoking details are
lacking. Prospective measurement of voice quality is also
not available in this retrospective review.
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